Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063203 · ClinicalTrials.gov registry record · Phase 2
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03063203: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT03063203 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03063203, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.
Primary Outcome
* Overall survival (OS) is defined as the time from enrollment to death due to any cause. For a patient who is not known to be alive at the end of study follow up, observation of OS is censored on the date the patient was last known to be alive * To be evaluable for this outcome measure the participant would have to have received at least one dose of decitabine
Interventions
- DRUG Decitabine
- PROCEDURE Peripheral blood draw
- PROCEDURE Buccal swab
- PROCEDURE Skin biopsy
- PROCEDURE Bone marrow biopsy/aspirate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
Why NCT03063203 stopped before completion
NCT03063203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Decitabine is the first listed.
NCT03063203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03063203 about?
NCT03063203 is a clinical study titled "Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia". In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.
What is the current status of trial NCT03063203?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-07-14. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03063203?
The interventions under investigation include: Decitabine (DRUG), Peripheral blood draw (PROCEDURE), Buccal swab (PROCEDURE), Skin biopsy (PROCEDURE), Bone marrow biopsy/aspirate (PROCEDURE).
Who is sponsoring clinical trial NCT03063203?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03063203's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI